Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specialising in orphan diseases. Under this agreement, Sperogenix will in-license the drug candidate Vamorolone